Key result
Nanoencapsulated cilostazol fails to change aortic thickness but improves HDL and triglycerides in rats.
Why the study?
Nanocapsules may optimize cilostazol pharmacokinetics and pharmacodynamics at the vascular level for preventing atherosclerosis, but their effects on arterial tunics and lipid profile are not established.
Does nanoencapsulated cilostazol improve abdominal aortic tunics and lipid profile in Wistar rats?
Does nanoencapsulated cilostazol improve abdominal aortic tunics and lipid profile in Wistar rats?
Nanoencapsulated cilostazol improved lipid profiles but did not alter aortic tunic histology in Wistar rats over 30 days.
No clinical translation supported by rat data; leaves open whether lipid improvements merit human trials.
Cilostazol (CLZ) is a phosphodiesterase III inhibitor with antiplatelet and vasodilator properties. It has been recently verified that CLZ plays a significant role in the arteries by inhibiting the proliferation and growth of muscle cells, increasing the release of nitric oxide by the endothelium and promoting angiogenesis. Considering these promising effects, the use of nanocapsules may be an interesting strategy to optimize its pharmacokinetics and pharmacodynamics at the vascular level for preventing atherosclerosis. The aim of this study was to evaluate the effect of cilostazol-loaded nanocapsules in the abdominal aortic tunics and on the lipid profile of Wistar rats in order to investigate its potential role in the prevention of atherosclerosis. Thirty-two animals were divided into four groups of eight animals, with 30-day treatment. Group 1 received nanoencapsulated CLZ; Group 2, control nanocapsules with no drug; Group 3, propylene glycol and water; and Group 4, a solution of CLZ in propylene glycol and water. After 30 days, there was no statistically significant difference between the groups regarding the cellularity and thickness of the arterial tunics of the abdominal aorta. However, the group that received nanoencapsulated CLZ (Group 1) had an improvement in HDL-c and triglyceride values compared to unloaded nanocapsules (Group 2).
No takes yet. Share an insight, caveat, or question.
Pilatti et al. (2020) studied Atherosclerosis prevention (n=32). Cilostazol-loaded nanocapsules vs. Unloaded nanocapsules, vehicle, and free cilostazol solution was evaluated on Cellularity and thickness of the arterial tunics of the abdominal aorta, and lipid profile. Nanoencapsulated cilostazol did not significantly change abdominal aorta tunic thickness but improved HDL-c and triglyceride values compared to unloaded nanocapsules in Wistar rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: